AKTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Aktis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$15.11+0.05 (+0.33%)
Close on Oct 19, 2026
- Market cap
- $835.58M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
61.4%
34M of 56M shares
Institutional holders
114
53 new, 6 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
9 buys · 11 sales
Net bought $111.08M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Eli Lilly and Company | 6,344,114 | 11.90% | 13D (active) | Jan 12, 2026 |
| Helen Kim | 5,831,315 | 10.90% | 13D (active) | Jan 12, 2026 |
| Oleg Nodelman | 4,862,335 | 9.10% | 13D (active) | Jan 12, 2026 |
| Blue Owl Capital Holdings LP | 3,161,348 | 5.92% | 13G (passive) | Mar 31, 2026 |
| Ansbert Gadicke | 10,260,064 | 19.30% | 13D (active) | Jan 12, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AKTS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mpm Bioimpact LLC | 4,835,872 | 8.69% | $155.86M | – | 9.50% |
| EcoR1 Capital, LLC | 4,824,469 | 8.67% | $155.49M | – | 7.56% |
| Blue Owl Capital Holdings LP | 3,070,219 | 5.52% | $98.95M | −91,129 | 14.89% |
| BlackRock, Inc. | 2,278,358 | 4.10% | $73.43M | +166,231 | 0.00% |
| T. Rowe Price Investment Management, Inc. | 2,051,447 | 3.69% | $66.12K | −72,365 | 0.04% |
| Wellington Management Group Llp | 1,966,244 | 3.54% | $63.37M | −350,800 | 0.01% |
| Rtw Investments, LP | 1,592,043 | 2.86% | $51.31M | – | 0.44% |
| Ra Capital Management, L.P. | 1,314,405 | 2.36% | $42.36M | −188,679 | 0.37% |
| Jupiter Topco LLC | 1,314,267 | 2.36% | $42.36M | New | 0.02% |
| Baker Bros. Advisors LP | 996,351 | 1.79% | $32.11M | – | 0.16% |
| Octagon Capital Advisors LP | 960,847 | 1.73% | $30.97M | – | 2.78% |
| Merck & Co., Inc. | 952,844 | 1.71% | $30.71M | – | 5.83% |
| Vanguard Capital Management LLC | 817,075 | 1.47% | $26.33M | −16,838 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 763,499 | 1.37% | $24.61K | −800,697 | 0.00% |
| TCG Crossover Management, LLC | 696,560 | 1.25% | $22.45M | New | 0.54% |
| Geode Capital Management, LLC | 520,737 | 0.94% | $16.79M | +28,801 | 0.00% |
| Eventide Asset Management, LLC | 507,000 | 0.91% | $16.34M | – | 0.22% |
| Avidity Partners Management LP | 484,200 | 0.87% | $15.61M | −452,932 | 2.50% |
| State Street Corp | 484,010 | 0.87% | $15.60M | +55,757 | 0.00% |
| a16z Capital Management, L.L.C. | 415,000 | 0.75% | $13.38M | – | 0.09% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 114 | 34M | 61.4% | 53 / 27 | 18 / 6 | 3M | 3M |
| Q1 2026 | 69 | 35M | 63.3% | 69 / 0 | 0 / 0 | 35M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AKTS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Health Care Fund | 1,462,244 | 2.63% | $32.27M | 0.08% | Jul 31, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 676,577 | 1.22% | $21.81M | 0.23% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 585,135 | 1.05% | $18.86M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 545,302 | 0.98% | $17.58M | 0.02% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 507,000 | 0.91% | $16.34M | 0.91% | Jun 30, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 358,947 | 0.65% | $11.57M | 0.23% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 333,745 | 0.60% | $10.76M | 0.09% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 283,355 | 0.51% | $5.88M | 0.11% | May 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 266,503 | 0.48% | $5.53M | 0.09% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 232,435 | 0.42% | $5.13M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 209,816 | 0.38% | $6.76M | 0.01% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 196,735 | 0.35% | $6.34M | 0.04% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Value Fund, Inc. | 163,403 | 0.29% | $5.27M | 0.05% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 133,328 | 0.24% | $4.30M | 0.03% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 105,593 | 0.19% | $2.19M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew Roden | President and CEO, Director | 91,998 | 0.17% | Jan 8, 2026 |
| Akos Czibere | Chief Medical Officer | 0 | – | Sep 24, 2026 |
| Shulamit Ron-Bigger | Chief Operating Officer | 34,200 | 0.06% | Jul 10, 2026 |
| Paul L. Feldman | Chief Scientific Officer | 144,568 | 0.26% | Jan 8, 2026 |
| Kyle D. Kuvalanka | Chief Financial Officer | – | – | Jan 8, 2026 |
| Ken Herrmann | Director | 3,506 | 0.01% | Jul 21, 2026 |
| Glenn Gormley | Director | – | – | Apr 16, 2026 |
| Todd Foley | Director, 10% owner | 4,002,533 | 7.20% | Jan 14, 2026 |
| Helen Susan Kim | Director, 10% owner | 5,671,825 | 10.20% | Jan 12, 2026 |
| Oleg Nodelman | Director | 433,527 | 0.78% | Jan 12, 2026 |
| EcoR1 Capital, LLC | Director | – | – | Jan 12, 2026 |
| Lloyd Mitchell Segal | Director | 19,631 | 0.04% | Jan 12, 2026 |
| Michael A. Sherman | Director | – | – | Jan 8, 2026 |
| Mary Thistle | Director | – | – | Jan 8, 2026 |
| LILLY & Co ELI | 10% owner | 6,344,114 | 11.41% | Jan 15, 2026 |
| BioVentures 2018 GP LLC MPM | 10% owner | – | – | Jan 14, 2026 |
| Mpm Bioventures 2018, L.P. | 10% owner | – | – | Jan 14, 2026 |
| BioVentures 2018 LLC MPM | 10% owner | – | – | Jan 14, 2026 |
| Ansbert Gadicke | 10% owner | 7,570,168 | 13.61% | Jan 14, 2026 |
| Asset Management Investors Bv2018 Llc Mpm | 10% owner | – | – | Jan 14, 2026 |
| Oncology Innovations Fund GP LLC MPM | 10% owner | 341,709 | 0.61% | Jan 14, 2026 |
| Oncology Innovations Fund Lp Mpm | 10% owner | 10,260,064 | 18.45% | Jan 14, 2026 |
| Asset Management Llc Mpm | 10% owner | – | – | Jan 14, 2026 |
| Oncology Impact Private Investment Fund 2, L.P. | 10% owner | 341,709 | 0.61% | Jan 14, 2026 |
| Luke Evnin | 10% owner | – | – | Jan 14, 2026 |
| Mpm Bioventures 2018 (B), L.P. | 10% owner | – | – | Jan 14, 2026 |
| Vida Ventures Ii-A, Llc | 10% owner | 5,671,825 | 10.20% | Jan 12, 2026 |
| Vida Ventures II, LLC | 10% owner | – | – | Jan 12, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Akos Czibere Chief Medical Officer | Sep 23, 2026 | Sale(10b5-1 plan) | −7,401 | $21.03 | $155.64K | 0 |
| Akos Czibere Chief Medical Officer | Sep 23, 2026 | Sale(10b5-1 plan) | −5,099 | $20.19 | $102.95K | 7,401 |
| Akos Czibere Chief Medical Officer | Sep 23, 2026 | Option exercise | +12,500 | $4.95 | $61.88K | 12,500 |
| Ken Herrmann Director | Jul 20, 2026 | Option exercise | +3,506 | $0.08 | $280 | 3,506 |
| Ken Herrmann Director | Jul 20, 2026 | Option exercise | +1,350 | $1.91 | $2.58K | 4,856 |
| Ken Herrmann Director | Jul 20, 2026 | Sale | −3,506 | $24.56 | $86.11K | 1,350 |
| Ken Herrmann Director | Jul 20, 2026 | Sale | −1,350 | $24.56 | $33.16K | 0 |
| Ken Herrmann Director | Jul 17, 2026 | Sale | −3,065 | $25.21 | $77.27K | 0 |
| Ken Herrmann Director | Jul 17, 2026 | Option exercise | +3,065 | $0.08 | $245 | 3,065 |
| Akos Czibere Chief Medical Officer | Jul 8, 2026 | Sale | −4,371 | $28.71 | $125.49K | 0 |
| Akos Czibere Chief Medical Officer | Jul 8, 2026 | Sale | −30,829 | $27.95 | $861.67K | 4,371 |
| Akos Czibere Chief Medical Officer | Jul 8, 2026 | Sale | −14,800 | $27.13 | $401.52K | 35,200 |
| Akos Czibere Chief Medical Officer | Jul 8, 2026 | Option exercise | +50,000 | $4.95 | $247.50K | 50,000 |
| Shulamit Ron-Bigger Chief Operating Officer | Jul 8, 2026 | Sale | −15,800 | $27.13 | $428.65K | 34,200 |
| Shulamit Ron-Bigger Chief Operating Officer | Jul 8, 2026 | Option exercise | +50,000 | $3.66 | $183.00K | 50,000 |
| Shulamit Ron-Bigger Chief Operating Officer | Jul 8, 2026 | Sale | −30,000 | $27.94 | $838.20K | 4,200 |
| Shulamit Ron-Bigger Chief Operating Officer | Jul 8, 2026 | Sale | −4,200 | $28.75 | $120.75K | 0 |
| Todd Foley Director, 10% owner | Jan 12, 2026 | Conversion | +716,872 | – | – | 4,002,533 |
| Todd Foley Director, 10% owner | Jan 12, 2026 | Conversion | +597,391 | – | – | 597,391 |
| Todd Foley Director, 10% owner | Jan 12, 2026 | Buy | +232,870 | $18.00 | $4.19M | 4,235,403 |
| Todd Foley Director, 10% owner | Jan 12, 2026 | Conversion | +2,688,270 | – | – | 3,285,661 |
| Ansbert Gadicke 10% owner | Jan 12, 2026 | Conversion | +5,914,197 | – | – | 7,570,168 |
| Ansbert Gadicke 10% owner | Jan 12, 2026 | Conversion | +1,577,119 | – | – | 9,147,287 |
| Ansbert Gadicke 10% owner | Jan 12, 2026 | Buy | +1,112,777 | $18.00 | $20.03M | 10,260,064 |
| Ansbert Gadicke 10% owner | Jan 12, 2026 | Conversion | +1,314,262 | – | – | 1,655,971 |
| Oncology Innovations Fund Lp Mpm 10% owner | Jan 12, 2026 | Buy | +1,112,777 | $18.00 | $20.03M | 10,260,064 |
| Oncology Innovations Fund Lp Mpm 10% owner | Jan 12, 2026 | Conversion | +1,314,262 | – | – | 1,655,971 |
| Oncology Innovations Fund Lp Mpm 10% owner | Jan 12, 2026 | Conversion | +5,914,197 | – | – | 7,570,168 |
| Oncology Innovations Fund Lp Mpm 10% owner | Jan 12, 2026 | Conversion | +1,577,119 | – | – | 9,147,287 |
| Helen Susan Kim Director, 10% owner | Jan 12, 2026 | Buy | +812,455 | $18.00 | $14.62M | 5,671,825 |
| Helen Susan Kim Director, 10% owner | Jan 12, 2026 | Conversion | +134,842 | – | – | 134,842 |
| Helen Susan Kim Director, 10% owner | Jan 12, 2026 | Buy | +22,545 | $18.00 | $405.81K | 157,387 |
| Helen Susan Kim Director, 10% owner | Jan 12, 2026 | Conversion | +4,859,370 | – | – | 4,859,370 |
| Lloyd Mitchell Segal Director | Jan 12, 2026 | Conversion | +19,631 | – | – | 19,631 |
| Oleg Nodelman Director | Jan 12, 2026 | Buy | +144,443 | $18.00 | $2.60M | 347,305 |
| Oleg Nodelman Director | Jan 12, 2026 | Conversion | +2,270,879 | – | – | 2,270,879 |
| Oleg Nodelman Director | Jan 12, 2026 | Conversion | +202,862 | – | – | 202,862 |
| Oleg Nodelman Director | Jan 12, 2026 | Conversion | +128,506 | – | – | 128,506 |
| Oleg Nodelman Director | Jan 12, 2026 | Buy | +2,077,779 | $18.00 | $37.40M | 4,348,658 |
| Vida Ventures Ii-A, Llc 10% owner | Jan 12, 2026 | Buy | +812,455 | $18.00 | $14.62M | 5,671,825 |
| Vida Ventures Ii-A, Llc 10% owner | Jan 12, 2026 | Conversion | +134,842 | – | – | 134,842 |
| Vida Ventures Ii-A, Llc 10% owner | Jan 12, 2026 | Buy | +22,545 | $18.00 | $405.81K | 157,387 |
| Vida Ventures Ii-A, Llc 10% owner | Jan 12, 2026 | Conversion | +4,859,370 | – | – | 4,859,370 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Czibere Akos Officer | Sep 23, 2026 | 25,000 | $552.75K | Sep 23, 2026 | Exercise of Stock Options |
| Herrmann Ken Director | Jul 20, 2026 | 4,856 | $119.27K | Jul 20, 2026 | Stock Option Exercise |
| Herrmann Ken Director | Jul 17, 2026 | 3,065 | $77.26K | Jul 17, 2026 | Stock Option Exercise |
| Czibere Akos Officer | Jul 8, 2026 | 50,000 | $1.39M | Jul 8, 2026 | Exercise of Options Under a Registered Plan |
| Ron-Bigger Shulamit Officer | Jul 8, 2026 | 50,000 | $1.39M | Jul 8, 2026 | Exercise of Options Under a Registered Plan |